Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Pfizer-Allergan deal: what next for contract manufacturers?

As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation.

PCT 2015

Strategic CRO relationships no more effective than traditional models, Tufts

Inconsistent practices and a lack of trust are restricting sponsors from fully realising the potential of CRO strategic partnerships, according to Tufts' Director Kenneth Getz.

Xellia buys ex-Ben Venue site and aims to restart production in 2017

Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.

Eisai to sell clinical diagnostics supply business

Eisai will sell its clinical diagnostics business – EIDIA Co. Ltd - to Sekisui Chemical for JPY 22.4bn ($183m).

Cyprotex: Predictive toxicology tech will help pharma cut animal study spending

Cyprotex has expanded its toxicology offering with a new in silico tech it claims will reduce preclinical costs and cut the number of animal studies required.

Megamerger Pfall-out? $160bn Pfizer-Allergan deal to hit CROs in short-term, analysts

The $160bn Pfizer-Allergan megamerger could lead to booking cancellations in the short-term say analysts, but CROs – especially Icon, Parexel and PPD - should ultimately benefit.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...